Mutual Funds Commodities Research Tax Planning IPO Our Team Contact Us  
Google
Web www.equitybulls.com
Stock Report

| More

Bharat Biotech Announces Phase 3 Results of COVAXIN®: India's First COVID-19 Vaccine Demonstrates Interim Clinical Efficacy of 81%

Posted On: 2021-03-03 08:55:31 (Time Zone: Arizona, USA)


Bharat Biotech, a global leader in vaccine innovation, developing vaccines for infectious diseases, today announced the first interim analysis of its BBV152 (COVAXIN®). The whole virion inactivated COVID-19 vaccine candidate demonstrated an interim vaccine efficacy of 81% in its Phase 3 clinical trial. The trials involved 25,800 subjects, the largest ever conducted in India, in partnership with the Indian Council of Medical Research.

"Today is an important milestone in vaccine discovery, for science and our fight against coronavirus. With today's results from our Phase 3 clinical trials, we have now reported data on our COVID-19 vaccine from Phase 1, 2, and 3 trials involving around 27,000 participants.

COVAXIN® demonstrates high clinical efficacy trend against COVID-19 but also significant immunogenicity against the rapidly emerging variants," said Dr. Krishna Ella, Chairman & Managing Director, Bharat Biotech.

BBV152 contains a whole virion inactivated SARS-CoV-2 vaccine, which is produced in Vero cells. It is stable at 2 to 8°C (refrigerated) and is shipped in a ready-to-use liquid formulation that permits distribution using existing vaccine supply chain channels. BBV152 has a 28-day open vial policy as a unique product characteristic, thus reducing vaccine wastage by approximately 10-30%.

BBV152 is based on an established manufacturing platform with a better safety profile when compared to other vaccine platforms. The inclusion of the Algel-IMDG adjuvant enhances T-cell immune responses to COVID-19, leading to long-term protection.

"I want to thank every one of the participants, who volunteered to participate in this vital clinical trial, our partners, principal investigators across 25 study sites, and our team at Bharat Biotech who dedicated their time to this vaccine discovery," said Mrs. Suchitra Ella, Joint Managing Director, Bharat Biotech. "We could not have achieved this public-private partnership milestone without the relentless commitment of those involved."

Interim Phase 3 Results: 81% Efficacy

The Phase 3 study enrolled 25,800 participants between 18-98 years of age, including 2,433 over the age of 60 and 4,500 with comorbidities. The primary endpoint of Phase 3 clinical trial is based on the first occurrence of PCR-confirmed symptomatic (mild, moderate, or severe) COVID-19 with onset at least 14 days after the second study vaccination in serologically negative (to SARS-CoV-2) adult participants at baseline.

The first interim analysis is based on 43 cases, of which 36 cases of COVID-19 were observed in the placebo group versus 7 cases observed in the BBV152 (COVAXIN®) group, resulting in a point estimate of vaccine efficacy of 80.6%.

The interim analysis included a preliminary review of the safety database, which showed that severe, serious, and medically attended adverse events occurred at low levels and were balanced between vaccine and placebo groups. The trial's conduct and monitoring are as per Good Clinical Practice guidelines and have been outsourced to IQVIA.

Analysis from the National Institute of Virology indicates that vaccine-induced antibodies can neutralize the UK variant strains and other heterologous strains, which has been published in bioRxiv. https://doi.org/10.1101/2021.01.26.426986

Bharat Biotech expects to share further details of the trial results as additional data become available. An additional interim analysis is planned for 87 cases, and the final analysis is planned for 130 cases. All data from the second interim and final analyses will be shared via pre-publication servers as well as submitted to a peer-reviewed journal for publication.

More than 40 countries globally have expressed their interest in COVAXIN®. These countries are highly satisfied with the safe, inactivated vaccine technology and robust data package for safety and immunogenicity.


Source: Equity Bulls

Click here to send ur comments or to feedback@equitybulls.com





Other Headlines:

Vedanta Resources Limited's stake in Vedanta Ltd increases to 65.2% post open offer

Hindustan Hardy Limited shuts down Nashik Factory temporarily as per Covid19 guidelines

NHPC Limited inks promoter agreemetnt for Hydroelectic Power project

Bharti Airtel announces new corporate structure to sharpen focus on digital

Dhanvarsha Finvest Ltd allots 15,98,727 CCDs

Cyient Announces 'INTELLICYIENT' to Help Customers Accelerate Digital Industrial Transformation with Industry 4.0 Solutions

Infosys Ltd board approves buyback through open market route

Persistent named a Star Performer in Everest Group's Software Product Engineering Services PEAK Matrix® Assessment 2021

Infosys Limited board recommends final dividend of Rs. 15

TCS Recognized as a Leader in the 2021 Gartner Magic Quadrant for Managed Workplace Services, North America

Infosys Ltd posts Rs. 5076 crore consolidated PAT in Q4FY21

India's 1st TWS Manufacturer pTron launches its Made in India Smart Essentials Collection

Kotak Partners Mumbai Indians, Launches 2nd Innings of the MyTeam Image Card - Special Cricket Edition Debit & Credit Cards for MI Fans

Dr Soosan Jacob of Dr Agarwal's Eye Hospital Among Top 100 Women Ophthalmologists in the World

L&T Technology Services Ltd board to consider FY21 results, final dividend on May 3, 2021

Openreach selects STL as a strategic partner to help build its new UK Full Fibre network

Hero MotoCorp Ltd board to announce Q4, FY21 results and final dividend on May 6, 2021

Ujjivan Small Finance Bank partners with NIRA to provide Personal Loans

Eno goes hard against home remedies with its Gadbad Gadbad Campaign

Happiest Minds and Beatroute Partner to Offer Revenue Realization Solutions for CPG Industry

Majesco Ltd board to approve Q4, FY21 results on April 21, 2021

Sanofi India Ltd board to consider Q1CY2021 results on April 27, 2021

Muthoot Finance declares interim dividend of 200%

JSW Steel Limited arm completes acquisition of 30.73% stake in GSI Lucchini S.p.A

Acuité Ratings upgrades ratings of Mukand Ltd

5paisa Capital Board approves Fresh Capital Raise of Rs.2,508.70 million

Motherson Sumi Systems Ltd's rating outlook revised to Stable from Negative by Moody's

Adani Road Transport Limited forms subsidiary Badakumari Karki Road Private Limited

Australian court dismisses class action case against Advanta Seeds Pty Ltd., a subsidiary of UPL

Foods & Inns Ltd signs JV agreement with D Technology to produce Pectin

Kalyan Jewellers announces ₹100 crore worth of Giveaways to celebrate the auspicious occasion of Puthandu

Pearl Polymers Limited completes sale of business undertaking

NBCC India Ltd secures business of Rs. 518.20 crore in March 2021

Gravita India Limited selected for Rajasthan Export Award

Exide Industries Ltd increases stake in JV to 82.71%

GHCL Ltd board to announce FY21 results, dividend on April 28, 2021

Sasken Technologies Ltd board to consider Q4, FY21 results and final dividend on April 22, 2021

Ashoka Buildcon Ltd emerges Lowest Bidder for Gujarat Rail Infrastructure Development Corporation Limited Project

Adani Solar Energy Chitrakoot One Limited commissions 50 MW solar power plant

Jaguar Land Rover achieved retail sales of 123,483 vehicles in Q4FY21

Venus Remedies enters into Partnership with West Pharmaceutical Services,Inc. to Launch Cloti-Xa™ in India with NovaGuard' SA Pro Safety System

Benetton India & Timex India enter into a Licensing Agreement for design, manufacture and distribution of Benetton watches

Ramco Systems partners with EXSYN Aviation Solutions for aircraft data migration

Hindustan Copper Ltd allots 4,18,06,020 shares at Rs. 119.60 to QIBs

Satin will facilitate Covid-19 vaccination for all its employees

Larsen & Toubro begins constructing the 300MW Solar Plant in Saudi Arabia

Birlasoft launches Pega® Center of Excellence to help customers drive CX and automation programs with AI-led technologies

Adani Green Energy Ltd increases operational capacity to 3470 MW in FY21

TCS headcount increases to 488,649

Dr. Reddy's Laboratories gets Emergency Use authorisation for Sputnik V in India



Website Created & Maintained by : Chennai Scripts
West Mambalam, Chennai - 600 033,
Tamil Nadu, India

disclaimer copyright © 2005 - 2020